Embecta (EMBC) said Tuesday that the company has decided to discontinue its insulin patch pump program and initiate an organizational restructuring plan for expected annualized cost savings of $60 million to $65 million.
The company expects to incur costs of $35 million to $45 million in fiscal 2025 related to its restructuring plan, consisting of $25 million to $30 million for planned workforce reductions and other associated costs from the discontinuation, and $10 million to $15 million for asset impairments and write-offs.
Embecta said that these preliminary estimates may be revised after the completion of an ongoing analysis of the restructuring plan.
The company expects to complete the restructuring plan during the first half of fiscal 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.